CL2021001636A1 - Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar - Google Patents

Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar

Info

Publication number
CL2021001636A1
CL2021001636A1 CL2021001636A CL2021001636A CL2021001636A1 CL 2021001636 A1 CL2021001636 A1 CL 2021001636A1 CL 2021001636 A CL2021001636 A CL 2021001636A CL 2021001636 A CL2021001636 A CL 2021001636A CL 2021001636 A1 CL2021001636 A1 CL 2021001636A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical composition
arterial hypertension
pulmonary arterial
aprocitentan
Prior art date
Application number
CL2021001636A
Other languages
English (en)
Inventor
Dénes Csonka
Wassim Fares
Hans Hoogkamer
Koen Torfs
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2021001636A1 publication Critical patent/CL2021001636A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con dosis elevadas de macitentán, o sales farmacéuticamente aceptables, solvatos, hidratos o formas morfológicas de este, o de aprocitentán, y una composición farmacéutica que los comprende, para uso en el tratamiento y/o prevención de la hipertensión arterial pulmonar (HAP), y para la elaboración de un medicamento. Describe también un régimen de dosificación para el mismo uso, así como una combinación de macitentán, o de aprocitentán, con otro agente activo.
CL2021001636A 2018-12-21 2021-06-18 Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar CL2021001636A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2018086724 2018-12-21
EP2019051830 2019-01-25
EP2019060151 2019-04-18
EP2019066494 2019-06-21
EP2019067186 2019-06-27

Publications (1)

Publication Number Publication Date
CL2021001636A1 true CL2021001636A1 (es) 2022-02-18

Family

ID=69147670

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001636A CL2021001636A1 (es) 2018-12-21 2021-06-18 Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar

Country Status (19)

Country Link
US (3) US11234980B2 (es)
EP (1) EP3897646B1 (es)
JP (1) JP2022512493A (es)
KR (1) KR20210109558A (es)
CN (1) CN113194953A (es)
AU (1) AU2019410727A1 (es)
BR (1) BR112021011999A2 (es)
CA (1) CA3123990A1 (es)
CL (1) CL2021001636A1 (es)
CO (1) CO2021007186A2 (es)
FI (1) FI3897646T3 (es)
IL (1) IL284136A (es)
JO (1) JOP20210153A1 (es)
MA (1) MA54522A (es)
MX (1) MX2021007455A (es)
PH (1) PH12021551371A1 (es)
SG (1) SG11202105098VA (es)
WO (1) WO2020128017A1 (es)
ZA (1) ZA202105111B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49664A (fr) * 2017-02-27 2020-06-03 Idorsia Pharmaceuticals Ltd Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
SG11202105098VA (en) 2018-12-21 2021-06-29 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60118782T2 (de) 2000-12-18 2007-01-25 Actelion Pharmaceuticals Ltd. Neue sulfamiden und deren verwendung als endothelin-antagonisten
EP1928409B1 (en) * 2005-09-12 2012-09-12 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
NO2315587T3 (es) 2008-08-13 2018-03-24
KR20240068077A (ko) 2016-11-10 2024-05-17 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
MA49664A (fr) * 2017-02-27 2020-06-03 Idorsia Pharmaceuticals Ltd Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
SG11202105098VA (en) 2018-12-21 2021-06-29 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
TW202103703A (zh) 2019-04-05 2021-02-01 瑞士商艾克泰聯製藥有限公司 用於治療門脈肺高血壓之方法
MX2022006404A (es) 2019-11-26 2022-08-25 Actelion Pharmaceuticals Ltd Composicion farmaceutica para el tratamiento de la enfermedad vascular pulmonar y/o disfuncion cardiaca en pacientes paliados con fontan.

Also Published As

Publication number Publication date
WO2020128017A1 (en) 2020-06-25
US20210196715A1 (en) 2021-07-01
ZA202105111B (en) 2023-03-29
IL284136A (en) 2021-08-31
CO2021007186A2 (es) 2021-06-10
EP3897646B1 (en) 2024-05-22
EP3897646A1 (en) 2021-10-27
MX2021007455A (es) 2021-08-05
US11464777B2 (en) 2022-10-11
CA3123990A1 (en) 2020-06-25
JP2022512493A (ja) 2022-02-04
AU2019410727A1 (en) 2021-08-12
MA54522A (fr) 2022-03-23
BR112021011999A2 (pt) 2021-09-08
US11234980B2 (en) 2022-02-01
US20220096476A1 (en) 2022-03-31
TW202034923A (zh) 2020-10-01
FI3897646T3 (fi) 2024-06-26
PH12021551371A1 (en) 2021-11-29
CN113194953A (zh) 2021-07-30
US20230020241A1 (en) 2023-01-19
KR20210109558A (ko) 2021-09-06
JOP20210153A1 (ar) 2023-01-30
SG11202105098VA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
CL2021001636A1 (es) Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2016002848A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CL2018003390A1 (es) Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma.
CO2021011046A2 (es) Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR112282A1 (es) Uso de la combinación de cabotegravir y rilpivirina para preparar una forma farmacéutica
CL2014003326A1 (es) Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.
DOP2022000004A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
CL2018003707A1 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.
CO2017000354A2 (es) Desmopresina estabilizada
AR105087A1 (es) Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona
AR108280A1 (es) Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo
AR108792A1 (es) Composiciones que comprenden timolol
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
DOP2019000233A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta